Comparisons of weight changes between sodium‐glucose cotransporter 2 inhibitors treatment and glucagon‐like peptide‐1 analogs treatment in type 2 diabetes patients: A meta‐analysis

Abstract

Aims/IntroductionTo evaluate the efficacy of weight changes from baseline of the sodium‐glucose cotransporter 2 (SGLT2) inhibitors treatment and glucagon‐like peptide‐1 (GLP‐1) analogs treatment after comparisons with a placebo in type 2 diabetes patients, and the associated factors.Materials and MethodsStudies were searched from when recording began, June 2004, until June 2015, and re‐searched in July 2016, and placebo‐controlled randomized trials in type 2 diabetes patients with a study length of ≥12 weeks were included.ResultsA total of 97 randomized controlled trials were included. Compared with a placebo, treatment with SGLT2 inhibitors was associated with a significantly greater decrease in weight change from baseline (weighted mean differences −2.01 kg, 95% confidence interval −2.18 to −1.83 kg, P < 0.001). Compared with a placebo, changes with GLP ‐1 treatment were also associated with a comparable decrease in weight change from baseline (weighted mean differences −1.59 kg, 95% confidence interval −1.86 to −1.32 kg, P < 0.001). Meta‐regression analysis showed that the baseline age, sex, baseline glycated hemoglobin, diabetes duration or baseline body mass index were not associated with the weight change from baseline in SGLT2 inhibitors or in GLP‐1 treatment corrected by placebo. Comparisons of weight changes from baseline corrected by placebo between SGLT2 inhibitors and GLP‐1 treatment showed that the difference was not significant (P > 0.05).ConclusionsAccording to the present meta‐analysis, treatment with SGLT2 inhibitors and treatment with GLP‐1 analogs led to comparable weight changes from baseline, which are both with significance when compared with placebo treatment.

Effect of sodium glucose cotransporter 2 inhibitors on obstructive sleep apnea in patients with type 2 diabetes

“…Because the improvement in OSAS was related to the degree of weight loss, greater improvement would be expected with greater weight loss [16,17]. Furthermore, several studies have demonstrated that SGLT2i reduces BW [18][19][20]. However, correlation analysis in our study showed the opposite result, that is, the more BW decreased, the less AHI improved in patients with severe OSAS.…”

Ipragliflozin, a sodium–glucose cotransporter 2 inhibitor, reduces bodyweight and fat mass, but not muscle mass, in Japanese type 2 diabetes patients treated with insulin: A randomized clinical trial

“…A single‐arm study with ipragliflozin showed a significant reduction in total muscle mass compared with baseline, as assessed with BIA. Third, the present patients were relatively older and leaner than those in previous studies. Recent clinical trials showed the benefits of SGLT2 inhibitors for cardiovascular and renal outcomes, including heart failure.…”

A novel dual glucagon‐like peptide and glucagon receptor agonist SAR425899: Results of randomized, placebo‐controlled first‐in‐human and first‐in‐patient trials

“…Among the pharmacotherapeutic treatments available for T2D, glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) and sodium‐glucose co‐transporter‐2 inhibitors provide effective weight loss, while also reducing glycated haemoglobin (HbA1c). Treatment with GLP‐1RAs results in substantial weight loss in patients with T2D or obesity, primarily by increasing feelings of satiety and consequently reducing energy intake; however, an increase in energy expenditure has not been observed .…”